Moderna’s COVID-19 vaccine phase 2/3 pediatric trial underway
Moderna today announced the administration of first COVID-19 vaccine doses to participants between the ages of 6 months and 12 years old as part of a phase 2/3 clinical trial.
The trial will investigate the vaccine’s effectiveness and safety in 6,750 healthy pediatric participants. For this study, Moderna will investigate two dosing levels for those ages 2 to 12, and three dosing levels for those aged 6 months to 2 years old.
Related News Articles
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…